口咽癌长期生存者迟发性下组颅神经病变与症状负担相关
该横断面调查研究纳入889例口咽癌生存者,其中36例(4.0%)发生迟发性下组颅神经病变(LCNP)。多变量模型显示,迟发性LCNP与更严重的MDASI-HN前5项症状均分(系数1.54,95%CI 0.82-2.26)及吞咽/咀嚼困难、黏液、疲乏、呛咳、语音症状单项评分显著相关。
要点
- 口咽癌生存者迟发性LCNP发生率为4.0%(36/889)。
- 迟发性LCNP与更严重的癌症治疗相关症状负担独立相关。
- 吞咽困难、黏液、疲乏、呛咳和语音症状与迟发性LCNP关联显著。
核心结论
- 口咽癌生存者中迟发性LCNP与更严重的癌症治疗相关症状负担相关。
研究设计与样本
- 纳入者无病且完成治疗至少1年,数据分析时间为2017年10月10日至2018年3月15日。
- 迟发性LCNP定义为癌症治疗后3个月或更晚出现。
主要发现
- 36/889例(4.0%)口咽癌生存者发生迟发性LCNP;753例(84.7%)为男性,821例(92.4%)为白人,中位年龄56岁(范围32-84),中位生存时间7年(范围1-16)。
- 校正年龄、生存时间、性别、治疗方式、T分期、亚部位、放疗类型、吸烟及治疗前正常饮食后,迟发性LCNP与更差MDASI-HN前5项症状均分显著相关(系数1.54,95%CI 0.82-2.26)。
- 迟发性LCNP与吞咽或咀嚼困难(系数2.25,95%CI 1.33-3.18)、黏液(系数1.97,95%CI 1.03-2.91)、疲乏(系数1.35,95%CI 0.40-2.21)、呛咳(系数1.53,95%CI 0.65-2.41)及语音或言语症状(系数2.30,95%CI 1.60-3.03)单项评分显著相关。
- 多重比较校正后,迟发性LCNP与平均干扰评分无显著相关(平均干扰系数0.72,95%CI 0.09-1.35)。
临床怎么用
- 对口咽癌生存者应关注迟发性LCNP,其与吞咽、语音、疲乏等症状负担加重相关。
- 研究结果可能为LCNP监测和管理策略的制定与实施提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lower cranial neuropathy (LCNP) is a rare but potentially disabling result of radiotherapy and other head and neck cancer therapies. Survivors who develop late LCNP may experience profound functional impairment, with deficits in swallowing, speech, and voice. OBJECTIVE: To investigate the association of late LCNP with severity of cancer treatment-related symptoms and subsequent general functional impairment among oropharyngeal cancer (OPC) survivors. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional survey study analyzed 889 OPC survivors nested within a retrospective cohort of OPC survivors treated at MD Anderson Cancer Center from January 1, 2000, to December 31, 2013. Eligible survey participants were disease free and completed OPC treatment 1 year or more before the survey. Data analysis was performed from October 10, 2017, to March 15, 2018. EXPOSURES: Late LCNP defined by onset 3 months or more after cancer therapy. MAIN OUTCOMES AND MEASURES: The primary outcome variable was the mean of the top 5 most severely scored symptoms of all 22 core and head and neck cancer-specific symptoms from the MD Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-HN). Secondary outcomes included mean MDASI-HN interference scores and single-item scores of the most severe symptoms. Multivariate models regressed MDASI-HN scores on late LCNP status, adjusting for clinical covariates. RESULTS: Overall, 36 of 889 OPC survivors (4.0%) (753 [84.7%] male; 821 [92.4%] white; median [range] age, 56 [32-84] years; median [range] survival time, 7 [1-16] years) developed late LCNP. Late LCNP was significantly associated with worse mean top 5 MDASI-HN symptom scores (coefficient, 1.54; 95% CI, 0.82-2.26), adjusting for age, survival time, sex, therapeutic modality, T stage, subsite, type of radiotherapy, smoking, and normal diet before treatment. Late LCNP was also significantly associated with single-item scores for difficulty swallowing or chewing (coefficient, 2.25; 95% CI, 1.33-3.18), mucus (coefficient, 1.97; 95% CI, 1.03-2.91), fatigue (coefficient, 1.35; 95% CI, 0.40-2.21), choking (coefficient, 1.53; 95% CI, 0.65-2.41), and voice or speech symptoms (coefficient, 2.30; 95% CI, 1.60-3.03) in multivariable models. Late LCNP was not significantly associated with mean interference scores after correction for multiple comparisons (mean interference coefficient, 0.72; 95% CI, 0.09-1.35). CONCLUSIONS AND RELEVANCE: In this large survey study, OPC survivors with late LCNP reported worse cancer treatment-related symptoms, a finding suggesting an association between late LCNP and symptom burden. This research may inform the development and implementation of strategies for LCNP surveillance and management.
引用
- Aggarwal P, Zaveri JS, Goepfert RP, et al. Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 30193299. doi:10.1001/jamaoto.2018.1791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。